V
Via Nova Therapeutics
Innovative therapies for acute and subacute viral infections, leveraging rapid diagnostics and telemedicine advancements
About Via Nova Therapeutics
Via Nova Therapeutics is a pioneering startup in the healthcare sector, specifically in the field of virology. Their primary objective is to develop innovative therapies for viral diseases, with a particular emphasis on acute and subacute infections. Unlike many in the industry who focus on chronic viral infections, Via Nova is carving a new path, hence their name which translates from Latin to 'New Road'.
Their business model is centered around the discovery and development of these novel therapies and then efficiently bringing them to clinical use. They are capitalizing on the advent of rapid at-home and point-of-care diagnostics for these infections, which they believe opens up new opportunities to bring their treatments to the clinic.
Their target market is broad, encompassing anyone suffering from acute and subacute viral infections, a segment they believe represents the next frontier of unmet medical need in virology. They generate revenue through the development and sale of these innovative therapies to healthcare providers.
In simpler terms, Via Nova Therapeutics is a company that is working to find new treatments for viral diseases that come on quickly and can be severe but are not long-lasting (acute) or those that are not as severe but last a long time (subacute). They are focusing on these types of infections because they believe there is a big need for new treatments in this area. They make money by creating these treatments and selling them to doctors and hospitals.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2021 | $20M | $80M | Aditum Bio | — |
Growth signals
Latest recorded traffic for Via Nova Therapeutics is 950 monthly website visits, down 52.5% over the last three months. Via Nova Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Via Nova Therapeutics in the Berkeley ecosystem
The Via Nova Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Aditum Bio
Other known investors1 additional known investor
QB3
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Via Nova Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Via Nova Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










